GKOS vs OTLK
GKOS: Glaukos is a specialized ophthalmic company transforming eye care through innovative Micro-Invasive Glaucoma Surgery devices and proprietary sustained-release pharmaceutical therapies. OTLK: Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA review in the US for wet AMD treatment.
Side-by-side fundamentals
| Metric | GKOS | OTLK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $152.86 | $1.34 | |
| Market cap as of 2026-07-23 | $8.9B | $212M | |
| PEG as of 2026-07-23 | -1.09 | n/a | |
| Net margin as of 2026-07-23 | -34.3% | -1507.0% | GKOS higher |
| Gross margin as of 2026-07-23 | +78.1% | +4.0% | GKOS higher |
| Operating margin as of 2026-07-23 | -36.0% | -1806.2% | GKOS higher |
| ROE as of 2026-07-23 | -26.5% | -415.5% | GKOS higher |
| ROA as of 2026-07-23 | -20.1% | -300.6% | GKOS higher |
| Debt / equity as of 2026-07-23 | 0.10 | 3.04 | GKOS lower |
| Revenue growth (YoY) as of 2026-07-23 | +36.3% | -22.9% | GKOS higher |
| Revenue CAGR (3y) SEC XBRL | +21.5% | n/a | |
| Beta as of 2026-07-23 | 0.75 | 0.75 | |
| 1-year return as of 2026-07-22 close | +58.3% | -35.6% | GKOS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.